Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

This study has been completed.
Information provided by (Responsible Party):
BioCryst Pharmaceuticals Identifier:
First received: September 25, 2009
Last updated: January 18, 2012
Last verified: January 2012
The study will be conducted in two parts. The first is a parallel-group design, evaluating doses of 40 mg, 80 mg or 120 mg BCX-4208. The second part is planned as a dose-escalation study, evaluating higher doses including 160 mg, 240 mg and 320 mg BCX-4208. The study's primary endpoint is the change in uric acid in the blood compared to baseline measurement prior to treatment, assessed on Day 22.

Condition Intervention Phase
Drug: placebo
Drug: BCX4208
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-Blind, Dose-Ranging, Two-Part, Multi-Center Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With Gout

Resource links provided by NLM:

Further study details as provided by BioCryst Pharmaceuticals:

Primary Outcome Measures:
  • To determine the effect of different doses of orally administered BCX4208 on serum uric acid (sUA)levels in subjects with gout. [ Time Frame: Day 22 ]

Enrollment: 99
Study Start Date: September 2009
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 40 mg
40 mg BCX4208
Drug: BCX4208
Administered daily for 21 days.
Experimental: 80 mg
Drug: BCX4208
Administered daily for 21 days.
Experimental: 120 mg
Drug: BCX4208
Administered daily for 21 days.
Placebo Comparator: sugar pill Drug: placebo
administered daily for 21 days
Experimental: 160mg
Drug: BCX4208
Administered daily for 21 days.
Experimental: 240mg
Drug: BCX4208
Administered daily for 21 days.
Experimental: 320mg
Drug: BCX4208
Administered daily for 21 days.

  Show Detailed Description


Ages Eligible for Study:   18 Years to 69 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥18 to <70 years
  2. Have read and signed the ICF after the nature of the study has been fully explained
  3. Screening sUA ≥8.0 mg/dL
  4. Diagnosis of gout according to the preliminary criteria of the American Rheumatism Association (1977)
  5. Female participants must meet at least one of the following specifications:

    • Be surgically sterile
    • Be post-menopausal as defined by:
    • females ≥55 years of age whose last menstrual period >1 year
    • females between ≥45 and <55 years of age whose last menstrual period > 1 year and FSH >40 mIU/mL and estradiol <40 pg/mL
    • Use oral contraceptives or some other form of hormonal birth control including hormonal vaginal rings or transdermal patches for 3 months prior to study drug dosing through 4 weeks after study drug administration
    • Use an intrauterine device as birth control for 8 weeks prior to study drug dosing through 4 weeks after study drug administration
    • Use (or ensure male partner[s]'s compliance with) a barrier contraception method (condom or diaphragm with a spermicide) for 4 weeks prior to study drug dosing through 4 weeks after study drug administration
  6. Male participants must be considered not of child-bearing potential defined as >1 year post-vasectomy or use a condom for 4 weeks prior to study drug dosing through 4 weeks after study drug administration. In addition, they must ensure their sexual partner complies with the female contraception requirements specified above.
  7. Be willing to avoid procreation for 3 months after study drug administration.
  8. Be willing and able to provide authorization for the use and disclosure of personal health information in accordance with Health Insurance Portability and Accountability policy.

Exclusion Criteria:

  1. Unstable angina
  2. History of cardiac arrhythmia
  3. History of congenital long QT
  4. Presence of cardiac signs or symptoms compatible with New York Heart Association Class III or Class IV functional status for congestive heart failure or angina
  5. Uncontrolled hypertension (above 150/95 mm Hg)
  6. History of moderate or severe renal impairment and/or previous clinical laboratory data indicating an estimated calculated creatinine clearance < 60 mL/min during the previous 12 months
  7. ALT/AST values >2.0 x ULN
  8. CD4+ cell counts by flow cytometry <500 cells/mm3 or >1600 cells/mm3
  9. Hemoglobin <12 g/dL or >17 g/dL (males) or < 11 g/dL or >16 g/dL (females)
  10. Hematocrit <37% or >51% (males) or <33 % or >47% (females)
  11. WBC <3.7 x 109/L or >11 X 109/L
  12. Immunocompromised due to illness or organ transplant
  13. Current use of systemic immunosuppressive medications or treatments
  14. Gout flare during the Screening Period that is resolved for less than 3 weeks prior to first treatment with study drug (exclusive of chronic synovitis/ arthritis)
  15. Recipient of any live, attenuated vaccine within 6 weeks of Screening
  16. History of clinically significant and relevant drug and/or food allergies
  17. History of chronic or recurrent infections
  18. History of any type of cancer (hematologic or solid tumor), that has required chemotherapy or radiation therapy in the previous 12 months, excluding non-melanomatous localized skin cancer
  19. Use of uric acid-lowering drugs within 30 days prior to the first dose of study drug or other prohibited medications within the timeframes specified in the protocol
  20. ACTH administration within 30 days of first treatment with study drug
  21. Intra-articular corticosteroid administration within 30 days of first treatment with study drug
  22. Systemic or oral glucocorticosteroid use within 4 weeks of first treatment with study drug or for a period of ≥ 6 months out of the last 12 months prior to the first treatment with study drug
  23. History of alcohol or drug abuse within the year prior to the signing of the ICF, or current evidence of substance dependence or abuse (alcohol intake > 3 drinks per day)
  24. Female subjects who are pregnant, planning a pregnancy or breastfeeding
  25. Positive pregnancy test
  26. Positive serology for hepatitis B or C surface antigen or human immunodeficiency virus (HIV) type 1
  27. Have been the recipient of any investigational drug within the last 30 days prior to the first treatment with study drug
  28. Other medical conditions which, in the opinion of the Principal Investigator, would jeopardize the safety of the study subject or impact the validity of the study results
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00985127

  Hide Study Locations
United States, Arizona
Radiant Research, Inc.
Scottsdale, Arizona, United States, 85251
Catalina Pointe Clinical Research
Tucson, Arizona, United States, 85704
United States, California
Irvine Center for Clinical Research
Irvine, California, United States, 92618
San Diego Arthritis Medical Clinic
San Diego, California, United States, 92108
United States, Florida
Avail Clinical Research
Deland, Florida, United States, 32720
Anchor Research Center
Naples, Florida, United States, 34102
United States, Hawaii
East-West Medical Research Institute
Honolulu, Hawaii, United States, 96814
United States, Idaho
Selah Medical Center
Boise, Idaho, United States, 83704
United States, Kentucky
Kentucky Medical Research Center
Lexington, Kentucky, United States, 40504
United States, Maryland
Arthritis & Osteoporosis Center of Maryland
Frederick, Maryland, United States, 21702
United States, Mississippi
Olive Branch Family Medical Center
Olive Branch, Mississippi, United States, 38654
United States, Missouri
Medex Healthcare Research
St. Louis, Missouri, United States, 63117
United States, Montana
Bozeman Urgent Care Center
Bozeman, Montana, United States, 59715
United States, Nebraska
Heartland Clinical Research
Omaha, Nebraska, United States, 68134
United States, Nevada
Arthritis Center of Reno
Reno, Nevada, United States, 89502
United States, New Mexico
New Mexico Clinical Research & Osteoporosis Center
Albuquerque, New Mexico, United States, 87106
United States, North Carolina
Triangle Medical Research Associates
Raleigh, North Carolina, United States, 27609
United States, Ohio
STAT Research
Dayton, Ohio, United States, 45417
United States, Oklahoma
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States, 73112
United States, Pennsylvania
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States, 16635
United States, South Carolina
Carolinas Center for Rheumatology & Arthritis
Rock Hill, South Carolina, United States, 29732
United States, South Dakota
Health Concepts
Rapid City, South Dakota, United States, 57702
United States, Texas
Renaissance Clinical Research
Dallas, Texas, United States, 75235
United States, Washington
Northwest Clinical Research Center
Bellevue, Washington, United States, 98004
Sponsors and Collaborators
BioCryst Pharmaceuticals
  More Information

Responsible Party: BioCryst Pharmaceuticals Identifier: NCT00985127     History of Changes
Other Study ID Numbers: BCX4208-201
Study First Received: September 25, 2009
Last Updated: January 18, 2012

Keywords provided by BioCryst Pharmaceuticals:

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases processed this record on May 25, 2017